Your session is about to expire
← Back to Search
Janus Kinase (JAK) Inhibitor
Ruxolitinib cream for Atopic Dermatitis
Phase 1
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, weeks 2, 4 and 8
Awards & highlights
Summary
This trial tests a cream called ruxolitinib on children with atopic dermatitis, a condition that makes their skin itchy and inflamed. The cream is applied regularly to see if it is safe and effective. It works by reducing inflammation and calming the immune system's response in the skin.
Eligible Conditions
- Atopic Dermatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1, weeks 2, 4 and 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, weeks 2, 4 and 8
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of treatment-emergent adverse events
Secondary study objectives
Accumulation ratio of Ruxilitinib
Plasma Css of Ruxolitinib
Trial Design
1Treatment groups
Experimental Treatment
Group I: Ruxolitinib creamExperimental Treatment1 Intervention
ruxolitinib 1.5% cream will be applied twice daily to all areas of the skin affected by AD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib cream
2022
Completed Phase 3
~1850
Find a Location
Who is running the clinical trial?
Incyte CorporationLead Sponsor
382 Previous Clinical Trials
57,023 Total Patients Enrolled
Innovaderm ResearchUNKNOWN
1 Previous Clinical Trials
40 Total Patients Enrolled
Haq Nawaz, MD, MPH, MBA, MSStudy DirectorIncyte Corporation
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger